"From our start to our reaching profitability, Atlas Venture has always supported Actelion's vision of pursuing excellence in medical innovation, clinical development, marketing and sales, even at times when that required significant faith in the outcome of our pipeline. Such attitude, balanced by sound financial judgment, is the best of what founders of biotech companies can expect from their venture-capital backers."
Dr. Jean-Paul Clozel, CEO and Founder
Actelion

We are typically the lead investor.  We take significant stakes in seed and early-stage businesses with extraordinary talent, visionary leadership, and proprietary assets; and also invest in select late-stage opportunities. A typical investment ranges from $5 million to $25 million over the life of the company.

We focus on markets where we have the experience, knowledge and network to help build a market leader. In our technology practice, our team looks for businesses in components, systems, software, and services. In our life sciences practice our team looks for companies in pharmaceuticals, drug discovery and medical devices.

We develop and investigate investment theses to help us find the best entrepreneurs and the most promising businesses.  Our team continuously researches investment spaces by studying underlying regulatory dislocations, economic changes and the shifting needs and desires of end customers. 

 

© 2005 Atlas Venture. All rights reserved.